On December 3, 2024, Richard Christopher, the Chief Executive Officer of Lexaria Bioscience Corp, purchased 50,000 shares of the company, according to a SEC Filing. This transaction marks the insider's total ownership at 50,000 shares.
Lexaria Bioscience Corp (LEXX, Financial) is a biotechnology company focused on enhancing the delivery of bioactive compounds through its proprietary DehydraTECH technology. The company aims to improve the speed and efficiency of drug delivery across various applications, including pharmaceuticals, nutraceuticals, and consumer products.
The insider transaction history for Lexaria Bioscience Corp indicates that there have been two insider buys and one insider sell over the past year. Richard Christopher's recent purchase is part of this trend, with the insider having bought 50,000 shares in total and sold none over the past year.
On the day of the purchase, shares of Lexaria Bioscience Corp were trading at $2.37 each, resulting in a market cap of $47.126 million. The company's stock is currently considered Significantly Overvalued based on its GF Value of $1.48, giving it a price-to-GF-Value ratio of 1.6.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company's past returns and growth, along with future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
